To access this material please log in or register

Register Authorize

Reduction of increased heart rate in arterial hypertension: clinical and predictive practicability

Kobalava Zh. D., Kiyakbaev G. K., Shavarov A. A.
Federal State Autonomous Educational Institution of Higher Education, “Russian University of Peoples’ Friendship”, Miklukho-Maklaya 6, Moscow 117198

Keywords: arterial hypertension, heart rate, arterial stiffness, beta-adrenergic blocker agents

DOI: 10.18087/rhj.2015.4.2102

Increased heart rate (HR) is an independent risk factor for all-cause mortality, sudden cardiac death, and cardiovascular (CV) death both in general population and individual subgroups. Data on the effect of pharmacologically slowed HR on prediction for patients with arterial hypertension (AH) who are characterized by tachycardia are far from being consistent. Results of some studies and meta-analyses have initiated debates on the place of β-blockers among hypotensive drugs in the aspect of reducing the risk for all-cause and cardiovascular mortality in this patient cohort. The review presents data that address the many-sided issue of clinical and practical significance of increased HR in AH.
  1. Singh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Сardiovasc Pharmacol Ther. 2001 Oct;6 (4):313–31.
  2. DiFrancesco D, Camm JA. Heart rate lowering by specific and selective If current inhibition with ivabradine: a new therapeutic perspective in cardiovascular disease. Drugs. 2004;64 (16):1757–65.
  3. Kannel WB, Kannel C, Paffenbarger RS Jr, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. Am Heart J. 1987 Jun;113 (6):1489–94.
  4. Gillum RF, Makuc DM, Feldman JJ. Pulse rate, coronary heart disease, and death: the NHANES I epidemiologic follow-up study. Am Heart J. 1991 Jan;121 (1 Pt 1):172–7.
  5. Wilhelmsen L, Berglund G, Elmfeldt D, Tibblin G, Wedel H, Pennert K et al. The multifactor primary prevention trial in Goteborg, Sweden. Eur Heart J. 1986 Apr;7 (4):279–88.
  6. Gillman MW, Kannel WB, Belanger A, D’Agostino RB. Influence of heart rate on mortality among persons with hypertension: The Framingham study. Am Heart J. 1993 Apr;125 (4):1148–54.
  7. Aronow WS, Ahn C, Mercando AD, Epstein S. Association of average heart rate on 24‑hour ambulatory electrocardiogram with incidence of new coronary events at 48‑month follow-up in 1,311 patients (mean age 81 years) with heart disease and sinus rhythm. Am J Cardiol. 1996 Nov 15;78 (10):1175–6.
  8. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected of proven coronary artery disease. Eur Heart J. 2005 May;26 (10):967–74.
  9. Copie X, Hnatkova K, Staunton A, Fei L, Camm AJ, Malik M. Predictive power of increased heart rate versus depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol. 1996 Feb;27 (2):270–6.
  10. Benetos A, Rudnichi A, Thomas F, Safar M, Guize L. Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension. 1999 Jan;33 (1):44–52.
  11. Palatini P. Heart rate: a strong predictor of mortality in subjects with coronary artery disease. Eur Heart J. 2005 May;26 (10):943–5.
  12. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U. S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334 (21):1349–55.
  13. Kjekshus JK. Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials. Am J Cardiol. 1986 Apr 25;57 (12):43F-49F.
  14. Kjekshus JK. Comments on beta-blockers: heart rate reduction, a mechanism of action. Eur Heart J. 1985;6:29–30.
  15. The Goteborg Metoprolol Trial in acute myocardial infarction. Am J Cardiol. 1984 Jun 25;53 (13) 1: D-50D.
  16. Reduction of infarct size with the early use of timolol in acute myocardial infarction. N Engl J Med. 1984 Jan 5;310 (1):9–15.
  17. Taylor SH, Silke B, Ebbutt A, Sutton Gc, Prout BJ, Burley DM. A long-term prevention study with oxprenolol in coronary heart disease. N Engl J Med. 1982 Nov 18;307 (21):1293–301.
  18. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. JAMA. 1993 Oct 6;270 (13):1589–95.
  19. Nul DR, Doval HC, Grancelli HO, Varini SD, Soifer S, Perrone SV et al. Heart rate is a marker of amiodarone mortality reduction in severe heart failure. J Am Coll Cardiol. 1997 May;29 (6):1199–205.
  20. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicentre Diltiazem Postinfarction Trial Research Group. N Engl J Med. 1988 Aug 18;319 (7):385–92.
  21. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II–DAVIT II). Am J Cardiol. 1990 Oct 1;66 (10):779–85.
  22. Messerli FH, Hansen JF, Gibson RS, Schechtman KB, Boden WE. Heart rate-lowering calcium antagonists in hypertensive post-myocardial infarction patients. J Hypertens. 2001 May;19 (5):977–82.
  23. Kjekshus J, Gullestad L. Heart rate as a therapeutic target in heart failure. Eur Heart J. 1999;1 (Suppl H): H64‑H69.
  24. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) a randomised trial against atenolol. Lancet. 2002 Mar 23;359 (9311):995–1003.
  25. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004 Nov 6–12;364 (9446):1684–9.
  26. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005 Oct 29 – Nov 4;366 (9496):1545–53.
  27. Palatini P, Dorigatti F, Zaetta V, Mormino P, Mazzer A, Bortolazzi A et al. Heart rate as a predictor of development of sustained hypertension in subjects screened for stage 1 hypertension: the HARVEST Study. J Hypertens. 2006 Sep;24 (9):1873–80.
  28. Inoue T, Iseki K, Iseki C, Kinjo K, Ohya Y, Takishita S. Higher heart rate predicts the risk of developing hypertension in a normotensive screened cohort. Circ J. 2007 Nov;71 (11):1755–60.
  29. Farinaro E, Stranges S, Guglielmucci G, Iermano P, Celentano E, Cajafa A, Trevisan M. Heart rate as a risk factor in hypertensive individuals. The Italian TensioPulse Study. Nutr Metab Cardiovasc Dis. 1999 Aug;9 (4):196–202.
  30. Чазова И. Е., Карпов Ю. А., Вигдорчик А. В. от лица исследовательской группы. Эффективность и безопасность комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: первые результаты российского наблюдательного исследования ЭКСТРА. Системные гипертензии. 2010;7 (2):20–27.
  31. Карпов Ю. А., Чазова И. Е., Вигдорчик А. В. от лица исследовательской группы. Эффективность и безопасность фиксированной комбинации амлодипина и валсартана в лечении артериальной гипертонии в условиях реальной клинической практики: результаты Российского наблюдательного исследования ЭКСТРА-2. Системные гипертензии. 2010;7 (4):14–20.
  32. Кобалава Ж. Д., Котовская Ю. В., Лукьянова Е. А. Комби­ни­ро­ванная терапия артериальной гипертонии с использованием фиксированной комбинации периндоприла аргинина / амлодипина в реальной клинической практике: организация и основные результаты программы КОНСТАНТА. Кардиология. 2013;56 (6):25–34.
  33. Morcet JF, Safar M, Thomas F, Guize L, Benetos A. Associations between heart rate and other risk factors in a large French population. J Hypertens. 1999 Dec;17 (12 Pt 1):1671–6.
  34. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G et al. Identification and management of the hypertensive patient with elevated heart rate: statement of a European Society of Hypertension Consensus Meeting. J Hypertens. 2006 Apr;24 (4):603–10.
  35. Palatini P. Heart rate as a cardiovascular risk factor: do women differ from men? Ann Med. 2001 May;33 (4):213–21.
  36. Palatini P, Mos L, Santonastaso M, Zanatta N, Mormino P, Saladini F et al. Resting heart rate as a predictor of body weight gain in the early stage of hypertension. Obesity (Silver Spring). 2011 Mar;19 (3):618–23.
  37. Shigetoh Y, Adachi H, Yamagishi S, Enomoto M, Fukami A, Otsuka M et al. Higher heart rate may predispose to obesity and diabetes mellitus: 20‑year prospective study in a general population. Am J Hypertens. 2009 Feb;22 (2):151–5.
  38. Carnethon MR, Yan L, Greenland P, Garside DB, Dyer AR, Metzger B, Daviglus ML. Resting heart rate in middle age and diabetes development in older age. Diabetes Care. 2008 Feb;31 (2):335–9.
  39. Carnethon MR, Golden SH, Folsom AR, Haskell W, Liao D. Prospective investigation of autonomic nervous system function and the development of type 2 diabetes: the Atherosclerosis Risk In Communities study, 1987–1998. Circulation. 2003 May 6;107 (17):2190–5.
  40. Mangoni AA, Microli L, Giannattasio C, Ferrari AU, Mancia G. Heart rate-dependence of arterial distensibility in vivo. J Hypertens. 1996 Jul;14 (7):897–901.
  41. Giannattasio C, Vincenti A, Failla M, Capra A, Ciro A, De Ceglia S et al. Effects of heart rate changes on arterial Distensibility in humans. Hypertension. 2003 Sep;42 (3):253–6.
  42. Sa Cunha R, Pannier B, Benetos A, Siche JP, London GM, Mallion JM, Safar ME. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens. 1997 Dec;15 (12 Pt 1):1423–30.
  43. Asmar R, Topouchian J, Pannier B, Benetos A, Safar M. Pulse wave velocity as endpoint in large-scale intervention trial. The COMPLIOR study. J Hypertens. 2001 Apr;19 (4):813–8.
  44. Benetos A, Adamopoulos C, Bureau JM, Temmar M, Labat C, Bean K et al. Determinants of accelerated progression of arterial stiffenss in normotensive and treated hypertensive subjects over a 6‑year period. Circulation. 2002 Mar 12;105 (10):1202–7.
  45. Inoue T, Iseki K, Iseki C, Ohya Y, Kinjo K, Takishita S. Heart rate as a risk factor for developing chronic kidney disease: longitudinal analysis of a screened cohort. Clin Exp Nephrol. 2009 Oct;13 (5):487–93.
  46. Bohm M, Reil JC, Danchin N, Thoenes M, Bramlage P, Volpe M. Association of heart rate with microalbuminuria in cardiovascular risk patients: data from I-SEARCH. J Hypertens. 2008 Jan;26 (1):18–25.
  47. Facila L, Pallares V, Peset A, Perez M, Gil V, Montagud V et al. Twenty-four-hour ambulatory heart rate and organ damage in primary hypertension. Blood Press. 2010 Apr;19 (2):104–9.
  48. Julius S, Palatini P, Kjeldsen S, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Schork MA, Hua T, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N. Tachycardia predicts cardiovascular events in the VALUE trial. American Society of Hypertension 2010 Scientific Meeting; May 1–4, 2010; New York, NY. Abstract LB-OR-01.
  49. Palatini P. Role of elevated heart rate in the development of cardiovascular disease in hypertension. Hypertension. 2011 Nov;58 (5):745–50.
  50. King DE, Everett CJ, Mainous AG, Liszka HA. Long-term prognostic value of resting heart rate in subjects with prehypertension. Am J Hypertens. 2006 Aug;19 (8):796–800.
  51. Bohn M, Cotton D, Foster L, Custodis F, Laufs U, Sacco R et al. Impact of resting heart rate on mortality, disability, cognitive decline in patients after ischaemic stroke. Eur Heart J. 2012 Nov;33 (22):2804–12.
  52. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007 Jun;25 (6):1105–87.
  53. Palatini P, Casiglia E, Julius S, Pessina AC. High heart rate: a risk factor for cardiovascular death in elderly men. Arch Intern Med. 1999 Mar 22;159 (6):585–92.
  54. Benetos A, Thomas F, Bean K, Albaladejo P, Palatini P, Guize L. Resting heart rate in older people: a predictor of survival to age 85. J Am Geriatr Soc. 2003 Feb;51 (2):284–5.
  55. Palatini P, Thijs L, Staessen JA, Fagard RH, Bulpitt CJ, Clement DL et al. Predictive value of clinic and ambulatory heart rate for morta­lity in elderly subjects with systolic hypertension. Arch Intern Med. 2002 Nov 11;162 (20):2313–21.
  56. Perk G, Stessman J, Ginsberg G, Bursztyn M. Sex differen­ces in the effect of heart rate on mortality in the elderly. J Am Geriatr Soc. 2003 Sep;51 (9):1260–4.
  57. Okamura T, Hayakawa T, Kadowaki T, Kita Y, Okayama A, Elliott P, Ueshima H. Resting heart rate and cause-specific death in a 16.5‑year cohort study of the Japanese general population. Am Heart J. 2004 Jun;147 (6):1024–32.
  58. Reunanen A, Karjalainen J, Ristola P, Heliovaara M, Knekt P, Aromaa A. Heart rate and mortality. J Intern Med. 2000 Feb;247 (2):231–9.
  59. Jouven X, Zureik M, Desnos M, Guerot C, Ducimetiere P. Resting heart rate as a predictive risk factor for sudden death in middle-aged men. Cardiovasc Res. 2001 May;50 (2):373–8.
  60. Hozawa A, Ohkubo T, Kikuya M, Ugajin T, Yamaguchi J, Asayama K et al. Prognostic value of home heart rate for cardiovascular morta­lity in the general population: the Ohasama study. Am J Hypertens. 2004 Nov;17 (11 Pt 1):1005–10.
  61. Jouven X, Empana JP, Schwartz PJ, Desnos M, Courbon D, Ducimetiere P. Heart-rate profile during exercise as a predictor of sudden death. N Engl J Med. 2005 May 12;352 (19):1951–8.
  62. Copie X, Hnatkova K, Staunton A, Fei L, Camm AJ, Malik M. Predictive power of increased heart rate vs. depressed left ventricular ejection fraction and heart rate variability for risk stratification after myocardial infarction. Results of a two-year follow-up study. J Am Coll Cardiol. 1996 Feb;27 (2):270–6.
  63. Marchioli R, Avanzini F, Barzi F, Chieffo C, Di Castelnuovo A, Franzoni MG et al. Assessment of absolute risk of death after myocardial infarction by use of multiple-risk-factor assessment equations: GISSI-Prevenzione mortality risk chart. Eur Heart J. 2001 Nov;22 (22):2085–103.
  64. Rambihar S, Gao P, Teo K, Bohm M, Yusuf S, Lonn E. Heart rate is associated with increased risk of major cardiovascular events, cardiovas- cular and all-cause death in patients with stable chronic cardiovascular disease: an analysis of ONTARGET / TRANSCEND. Circulation. 2010;122: A12667.
  65. Kolloch R, Legler UF, Champion A, Cooper-Dehoff RM, Handberg E, Zhou Q, Pepine CJ. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR / trandolapril STudy (INVEST). Eur Heart J. 2008 May;29 (10):1327–34.
  66. Salles GF, Cardoso CR, Fonseca LL, Fiszman R, Muxfeldt ES. Prognostic significance of baseline heart rate and its interaction with beta-blocker use in resistant hypertension: a cohort study. Am J Hypertens. 2013 Feb;26 (2):218–26.
  67. Palatini P, Winnicki M, Santonastaso M, De Venuto G, Zanata G, Bertolo O et al. Reproducibility of heart rate measured in the clinic and with 24‑hour intermittent recorders. Am J Hypertens. 2000 Jan;13 (1 Pt 1):92–8.
  68. Hozawa A, Inoue R, Ohkubo T, Kikuya M, Metoki H, Asayama K et al. Predictive value of ambulatory heart rate in the Japanese general population: the Ohasama study. J Hypertens. 2008 Aug;26 (8):1571–6.
  69. Hansen TW, Thijs L, Boggia J, Li Y, Kikuya M, Bjorklund-Bodegard K et al. Prognostic value of ambulatory heart rate revisited in 6928 subjects from 6 populations. Hypertension. 2008 Aug;52 (2):229–35.
  70. Sega R, Facchetti R, Bombelli M, Cesana G, Corrao G, Grassi G, Mancia G. Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation. 2005 Apr 12;111 (14):1777–83.
  71. Okin PM, Kjeldsen SE, Julius S, Hille DA, Dahlof B, Edelman Jm, Devereux RB. All-cause and cardiovascular mortality in relation to changing heart rate during treatment of hypertensive patients with electrocardiographic left ventricular hypertrophy. Eur Heart J. 2010 Sep;31 (18):2271–9.
  72. Paul L, Hastie CE, Li WS, Harrow C, Muir S, Connell JM et al. Resting heart rate pattern during follow-up and mortality in hypertensive patients. Hypertension. 2010 Feb;55 (2):567–74.
  73. Poulter NR, Dobson JE, Sever PS, Dahlof B, Wedel H, Campbell NR. Baseline heart rate, antihypertensive treatment, and prevention of cardiovascular outcomes in ASCOT (Anglo- Scandinavian Cardiac Outcomes Trial). J Am Coll Cardiol. 2009 Sep 22;54 (13):1154–61.
  74. Palatini P. Elevated heart rate in hypertension: a target for treatment? J Am Coll Cardiol. 2010 Mar 2;55 (9):931–2.
  75. Palatini P. Is there benefit of cardiac slowing drugs in the treatment of hypertensive patients with elevated heart rate? Eur Heart J. 2008 May;29 (10):1218–20.
  76. Custodis F, Baumhäkel M, Schlimmer N, List F, Gensch C, Bohm M, Laufs U. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008 May 6;117 (18):2377–87.
  77. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984 Oct 12;226 (4671):180–2.
  78. Guth BD, Indolfi С, Heusch G, Seitelberger R, Ross JJr. Mechanisms of benefit in the ischemic myocardium due to heart rate reduction. Basic Res Cardiol. 1990;85 (Suppl 1):157–66.
  79. Mulder P, Barbier S, Chagraoui A, Richard V, Henry JP, Lallemand F et al. Long-term heart rate reduction induced by the selective If current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure. Circulation. 2004 Apr 6;109 (13):1674–9.
  80. Cucherat M. Quantitative relationship between resting heart rate reduction and magnitude of clinical benefits in post-myocardial infarction: a meta-regression of randomized clinical trials. Eur Heart J. 2007 Dec;28 (24):3012–9.
  81. McAlister FA, Wiebe N, Ezekowitz JA, Leung AA, Armstrong PW. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med. 2009 Jun 2;150 (11):784–94.
  82. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009 Nov;27 (11):2121–58.
  83. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 May 19;338: b1665.
  84. Bangalore S, Sawhney S, Messerli FH. Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. J Am Coll Cardiol. 2008 Oct 28;52 (18):1482–9.
  85. Medical Research Council trial of treatment of hypertension in ol­der adults: principal results. MRC Working Party. BMJ. 1992 Feb 15;304 (6824):405–12.
  86. Кобалава Ж. Д., Киякбаев Г. К., Хомицкая Ю. В., Шаваров А. А. Достижение целевого уровня частоты сердечных сокращений покоя у пациентов со стабильной стенокардией и артериальной гипертонией на фоне терапии бета-адреноблокаторами в реальной клинической практике. Кардиология. 2013;53 (7):3–23.
  87. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP et al. 2012 ACCF / AHA / ACP / AATS / PCNA / SCAI / STS Guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol. 2012 Dec 18;60 (24):e44‑e164.
  88. Lehtonen A. Effect of beta blockers on blood lipid profile. Am Heart J. 1985 May;109 (5 Pt 2):1192–6.
  89. Cruickshank JM. Are we misunderstanding beta-blockers? Int J Cardiol. 2007 Aug 9;120 (1):10–27.
  90. Fogari R, Zoppi A. The clinical benefits of beta-1 selectivity. Rev Contemp Pharmacother. 1997;8:45–54.
  91. Lown B, Verrier RL. Neural activity and ventricular fibrillation. N Engl J Med. 1976 May 20;294 (21):1165–70.
  92. Freemantle N, Cleland J, Young P, Mason J, Harrison J. β Blockade after myocardial infarction: systematic review and meta-regression analysis. BMJ. 1999 Jun 26;318 (7200):1730–7.
  93. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure−lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation. 2006 Mar 7;113 (9):1213–25.
  94. Blacher J, Guerin АР, Pannier В, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999 May 11;99 (18):2434–9.
  95. Laurent S, Boutouyrie P, Asmar R, Gautier I, Laloux B, Guize L et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001 May;37 (5):1236–41.
  96. Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. 2002 Oct 15;106 (16):2085–90.
  97. Орлова Я. А., Макарова Г. В., Яровая Е. Б., Нуралиев Э. Ю., Агеев Ф. Т. Прогностическое значение различных параметров артериальной жесткости при ИБС. Сердце. 2009;8 (2):98–103.
  98. Stefanadis C, Dernellis J, Tsiamis E, Stratos C, Diamantopoulos L, Michaelides A, Toutouzas P. Aortic stiffness as a risk factor for recurrent acute coronary events in patients with ischaemic heart disease. Eur Heart J. 2000 Mar;21 (5):390–6.
  99. Vlachopoulos C, Aznaouridis K, O’Rourke MF, Safar ME, Baou K, Stefanadis C. Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis. Eur Heart J. 2010 Aug;31 (15):1865–71.
  100. Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007 Jul;50 (1):197–203.
  101. Pini R, Cavallini MC, Palmieri V, Marchionni N, Di Bari M, Devereux RB et al. Central but not brachial blood pressure predicts cardiovascular events in an unselected geriatric population: the ICARe Dicomano Study. J Am Coll Cardiol. 2008 Jun 24;51 (25):2432–9.
  102. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D et al. Differential impact of blood pressure lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CARE) study. Circulation. 2006 Mar 7;113 (9):1213–25.
  103. Jankowski P, Kawecka-Jaszcz K, Czarnecka D, Brzozowska-Kiszka M, Styczkiewicz K, Loster M et al. Pulsatile but not steady component of blood pressure predicts cardiovascular events in coronary patients. Hypertension. 2008 Apr;51 (4):848–55.
  104. Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc’h PM et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002 Mar 1;39 (3):735–8.
  105. Williams B, Lacy PS. Central aortic pressure and clinical outcomes. J Hypertens. 2009 Jun;27 (6):1123–5.
  106. Jondeau G, Korewicki J, Vasiliauskas D. Effect of ivabradine in patients with left ventricular systolic dysfunction and coronary artery disease. Eur Heart J. 2004;25 (Suppl): 451.
  107. Heidland UE, Stauer BE. Left ventricular muscle mass and elevated heart rate are associated with coronary plaque disruption. Circulation. 2001 Sep 25;104 (13):1477–82.
  108. Sa Cunha R, Pannier B, Benetos A, Siche JP, London GM, Mallion LM, Safar ME. Association between high heart rate and high arterial rigidity in normotensive and hypertensive subjects. J Hypertens. 1997 Dec;15 (12 Pt 1):1423–30.
  109. Tomiyama H, Hashimoto H, Tanaka H, Matsumoto C, Odaira M, Yamada J et al. Synergistic relationship between changes in the pulse wave velocity and changes in the heart rate in middle-aged Japanese adults: a prospective study. J Hypertens. 2010 Apr;28 (4):687–94.
  110. Saladini F, Benetti E, Mos L, Zanatta N, Zanata G, Cozzio S, Mormino P, Palatini P. Evolution of parameters of arterial distensibility in a cohort of young-to-middle-age hypertensive subjects. J Hypertens. 2010;28: e176.
  111. Van Bortel LM, Struijker-Boudier HA, Safar ME. Pulse pressure, arterial stiffness, and drug treatment of hypertension. Hypertension. 2001 Oct;38 (4):914–21.
  112. Орлова Я. А., Михайлов Г. В., Хежева Ф. М., Виценя М. В., Агеев Ф. Т. Влияние терапии бисопрололом на поКазатели периферического и центрального артериаЛьного давления, жесткость артерий, диастолическуЮ функцию левого желудочка и каЧество жизни у больных артериальной гипертонией (исследование КЛЮЧ). Сердце. 2012;11 (6):342–49.
  113. London GM, Asmar RG, O'Rourke MF, Safar ME. Mechanism (s) of selective systolic blood pressure reduction after a low-dose combination of perindopril / indapamide in hypertensive subjects: comparison with atenolol. J Am Coll Cardiol. 2004 Jan 7;43 (1):92–9.
  114. Boutouyrie P. Achouba A, Trunet P, Laurent S. Amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010 Jun;55 (6):1314–22.
  115. Sharman JE, Davies JE, Jenkins C, Marwick TH. Augmentation index, left ventricular contractility, and wave reflection. Hypertension. 2009 Nov;54 (5):1099–105.
  116. Fox KM, Ferrari R. Heart rate: a forgotten link in coronary artery disease? Nat Rev Cardiol. 2011 Apr 26;8 (7):369–79.
  117. Потапенко А. В., Буравлев М. Б., Шаваров А. А., Киякбаев К., Моисеев В. С., Кобалава Ж. Д. Влияние ивабрадина и атенолола на артериальную жесткость и центральное давление у больных стабильной стенокардией с артериальной гипертонией. Клиническая фармакология и терапия. 2012;21 (1):23–9.
  118. Thollon C, Vilaine JP. I (f) inhibition in cardiovascular diseases. Adv Pharmacol. 2010;59:53–92.
  119. Fox K, Ford I, Steg PG, Tardif JC, Tendera M, Ferrari Rl. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014 Sep 18;371 (12):1091–9.
  120. Dobre D, Borer JS, Fox K, Swedberg K, Adams KF, Cleland Jg et al. Heart rate: a prognostic factor and therapeutic target in chronic heart failure. The distinct roles of drugs with heart rate-lowering properties. Eur J Heart Fail. 2014 Jan;16 (1):76–85.
  121. Boutouyrie P, Bussy C, Hayoz D, Hengstler J, Dartois N, Laloux B et al. Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment. Circulation 2000 Jun 6;101 (22):2601–6.
  122. Kelly R, Daley J, Avolio A, O’Rourke M. Arterial dilation and reduced wave reflection: benefit of dilevalol in hypertension. Hypertension. 1989 Jul;14 (1):14–21.
  123. Dhakam Z, Yasmin, McEniery CM, Burton T, Brown T, Wilkinson IB. A comparison of atenolol and nebivolol in isolated systolic hypertension. J Hypertens. 2008 Feb;26 (2):351–6.
  124. Kampus P, Serg M, Kals J, Zagura M, Muda P, Karu K et al. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness. Hypertension. 2011 Jun;57 (6):1122–8.
  125. Polonia J, Barbosa L, Silva JA, Bertoquini S. Different patterns of peripheral versus central blood pressure in hypertensive patients treated with β-blockers either with or without vasodilator properties or with angiotensin receptor blockers. Blood Press Monit. 2010 Oct;15 (5):235–9.
  126. Mahmud A, Feely J. β-Blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens. 2008 Jun;21 (6):663–7.
  127. Shah NK, Smith SM, Nichols WW, Lo MC, Ashfaq U, Satish P et al. Carvedilol reduces aortic wave reflection and improves left ventri­cular / vascular coupling: a comparison with atenolol (CENTRAL Study). J Clin Hypertens. 2011 Dec;13 (12):917–24.
  128. Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M et al. 2013 ESH / ESC Guidelines for the management of Hypertension: the Task Forse for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Sosiety of Cardiology (ESC). J Hypertens. 2013 Jul;31 (7):1281–357.
  129. Weber MA, Schiffrin EL, White WB, Mann S, Lindholm LH, Kenerson JG et al. Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society of Hypertension. J Hypertens. 2014 Jan;32 (1):3–15.
  130. Недогода С. В. Бисопролол в лечении артериальной гипертензии. Российский Медицинский Журнал. 2011;4:192–4.
Kobalava Zh. D., Kiyakbaev G. K., Shavarov A. A. Reduction of increased heart rate in arterial hypertension: clinical and predictive practicability. Russian Heart Journal. 2015;14 (4):220–230

To access this material please log in or register

Register Authorize
Ru En